126 related articles for article (PubMed ID: 9175059)
1. Continuous administration of intravenous iron during haemodialysis.
Granolleras C; Zein A; Oulès R; Branger B; Fourcade J; Shaldon S
Nephrol Dial Transplant; 1997 May; 12(5):1007-8. PubMed ID: 9175059
[TBL] [Abstract][Full Text] [Related]
2. Safety of intravenous injection of iron saccharate in haemodialysis patients.
Sunder-Plassmann G; Hörl WH
Nephrol Dial Transplant; 1996 Sep; 11(9):1797-802. PubMed ID: 8918625
[TBL] [Abstract][Full Text] [Related]
3. 'Oversaturation' of transferrin after intravenous ferric gluconate (Ferrlecit(R)) in haemodialysis patients.
Zanen AL; Adriaansen HJ; van Bommel EF; Posthuma R; Th de Jong GM
Nephrol Dial Transplant; 1996 May; 11(5):820-4. PubMed ID: 8671901
[TBL] [Abstract][Full Text] [Related]
4. Experience with the use of an iron polymaltose (dextrin) complex given by single total dose infusion to stable chronic haemodialysis patients.
van Zyl-Smit R; Halkett JA
Nephron; 2002 Oct; 92(2):316-23. PubMed ID: 12218309
[TBL] [Abstract][Full Text] [Related]
5. Iron isomaltoside 1000: a new intravenous iron for treating iron deficiency in chronic kidney disease.
Wikström B; Bhandari S; Barany P; Kalra PA; Ladefoged S; Wilske J; Thomsen LL
J Nephrol; 2011; 24(5):589-96. PubMed ID: 21240875
[TBL] [Abstract][Full Text] [Related]
6. Nontransferrin-bound iron in the plasma of haemodialysis patients after intravenous iron saccharate infusion.
Kooistra MP; Kersting S; Gosriwatana I; Lu S; Nijhoff-Schutte J; Hider RC; Marx JJ
Eur J Clin Invest; 2002 Mar; 32 Suppl 1():36-41. PubMed ID: 11886430
[TBL] [Abstract][Full Text] [Related]
7. Low-dose continuous iron therapy leads to a positive iron balance and decreased serum transferrin levels in chronic haemodialysis patients.
Canavese C; Bergamo D; Ciccone G; Burdese M; Maddalena E; Barbieri S; Thea A; Fop F
Nephrol Dial Transplant; 2004 Jun; 19(6):1564-70. PubMed ID: 15004263
[TBL] [Abstract][Full Text] [Related]
8. Achieving optimal patient outcomes with intravenous iron.
Colfer M
Nephrol Nurs J; 2003 Aug; 30(4):449-53; quiz 454-5. PubMed ID: 14533524
[TBL] [Abstract][Full Text] [Related]
9. Iron supplementation in haemodialysis--practical clinical guidelines.
Silva J; Andrade S; Ventura H; Santos JP; Colaço S; Oliveira C; Ponce P
Nephrol Dial Transplant; 1998 Oct; 13(10):2572-7. PubMed ID: 9794562
[TBL] [Abstract][Full Text] [Related]
10. Weekly low-dose treatment with intravenous iron sucrose maintains iron status and decreases epoetin requirement in iron-replete haemodialysis patients.
Schiesser D; Binet I; Tsinalis D; Dickenmann M; Keusch G; Schmidli M; Ambühl PM; Lüthi L; Wüthrich RP
Nephrol Dial Transplant; 2006 Oct; 21(10):2841-5. PubMed ID: 16891647
[TBL] [Abstract][Full Text] [Related]
11. The safety of achieved iron stores and their effect on IV iron and ESA use: post-hoc results from a randomized trial of ferric citrate as a phosphate binder in dialysis
.
Umanath K; Greco B; Jalal DI; McFadden M; Sika M; Koury MJ; Niecestro R; Hunsicker LG; Greene T; Lewis JB; Dwyer JP
Clin Nephrol; 2017 Mar; 87 (2017)(3):124-133. PubMed ID: 28128726
[TBL] [Abstract][Full Text] [Related]
12. A protocol for coadministration of i.v. iron dextran and heparin in chronic hemodialysis patients.
Davis P; Bednarz D; Briglia A; Paganini EP
ANNA J; 1998 Oct; 25(5):533-8. PubMed ID: 9887705
[TBL] [Abstract][Full Text] [Related]
13. Effects of proactive iron and erythropoiesis-stimulating agent protocol implementation on achieving clinical guideline targets for anaemia in a satellite haemodialysis patient cohort.
Yong K; Kairaitis L
Nephrology (Carlton); 2010 Apr; 15(3):288-93. PubMed ID: 20470296
[TBL] [Abstract][Full Text] [Related]
14. Comparison of serum ferritin and transferrin saturation values associated with two i.v. iron formulations in hemodialysis patients.
Nguyen TV
Am J Health Syst Pharm; 2009 Jun; 66(12):1101-4. PubMed ID: 19498125
[TBL] [Abstract][Full Text] [Related]
15. TIDILAP: Treatment of iron deficiency in lipoprotein apheresis patients --A prospective observational multi-center cohort study comparing efficacy, safety and tolerability of ferric gluconate with ferric carboxymaltose.
Schatz U; Illigens BM; Siepmann T; Arneth B; Siegert G; Siegels D; Heigl F; Hettich R; Ramlow W; Prophet H; Bornstein SR; Julius U
Atheroscler Suppl; 2015 May; 18():199-208. PubMed ID: 25936327
[TBL] [Abstract][Full Text] [Related]
16. Oral versus intravenous iron supplementation in peritoneal dialysis patients.
Johnson DW; Herzig KA; Gissane R; Campbell SB; Hawley CM; Isbel NM
Perit Dial Int; 2001; 21 Suppl 3():S231-5. PubMed ID: 11887827
[TBL] [Abstract][Full Text] [Related]
17. Drug insight: Safety of intravenous iron supplementation with sodium ferric gluconate complex.
Michael B; Fishbane S; Coyne DW; Agarwal R; Warnock DG
Nat Clin Pract Nephrol; 2006 Feb; 2(2):92-100. PubMed ID: 16932400
[TBL] [Abstract][Full Text] [Related]
18. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study.
Coyne DW; Kapoian T; Suki W; Singh AK; Moran JE; Dahl NV; Rizkala AR;
J Am Soc Nephrol; 2007 Mar; 18(3):975-84. PubMed ID: 17267740
[TBL] [Abstract][Full Text] [Related]
19. Safety profile of iron polymaltose infusions.
Lee AYS; Leung SHP
Hosp Pract (1995); 2019 Apr; 47(2):96-98. PubMed ID: 30882255
[TBL] [Abstract][Full Text] [Related]
20. Transferrin oversaturation.
Strobos J; Weeda O; Seligman P; Nissenson A
Am J Kidney Dis; 1999 Aug; 34(2):401-2. PubMed ID: 10465728
[No Abstract] [Full Text] [Related]
[Next] [New Search]
